Beaumont Financial Advisors LLC trimmed its stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 1.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 9,444 shares of the financial services provider’s stock after selling 130 shares during the quarter. Beaumont Financial Advisors LLC’s holdings in iShares Biotechnology ETF were worth $1,375,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Future Financial Wealth Managment LLC purchased a new position in iShares Biotechnology ETF during the 1st quarter worth $27,000. Bbjs Financial Advisors LLC purchased a new position in iShares Biotechnology ETF during the 2nd quarter worth $31,000. Pacifica Partners Inc. grew its stake in iShares Biotechnology ETF by 118.2% during the 1st quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after buying an additional 130 shares during the last quarter. Mather Group LLC. purchased a new position in iShares Biotechnology ETF during the 1st quarter worth $57,000. Finally, Chris Bulman Inc purchased a new position in iShares Biotechnology ETF during the 2nd quarter worth $64,000. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Stock Performance
Shares of IBB stock opened at $143.15 on Friday. iShares Biotechnology ETF has a 1-year low of $111.83 and a 1-year high of $150.57. The stock’s fifty day moving average price is $145.10 and its 200 day moving average price is $139.27.
iShares Biotechnology ETF Dividend Announcement
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- How to Invest in Blue Chip Stocks
- 4 Quirky ETFs With Big Potential for Impressive Gains
- Best Aerospace Stocks Investing
- 2 Top Stocks Seeing Major Institutional Buying Right Now
- Want to Profit on the Downtrend? Downtrends, Explained.
- S&P 500 Hits Record Highs: 3 Stocks With Huge Growth Potential
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.